Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 947

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary

Whelton, Paul K., Carey, Robert M., Aronow, Wilbert S., Casey, Donald E., Collins, Karen J., Dennison Himmelfarb, Cheryl, DePalma, Sondra M., Gidding, Samuel, Jamerson, Kenneth A., Jones, Daniel W., MacLaughlin, Eric J., Muntner, Paul, Ovbiagele, Bruce, Smith, Sidney C., Spencer, Crystal C., Stafford, Randall S., Taler, Sandra J., Thomas, Randal J., Williams, Kim A., Williamson, Jeff D., Wright, Jackson T.·2018·Journal of the American Society of Hypertension
DOI 10.1016/j.jash.2018.06.010
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jash.2018.06.010

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 90 references

Research works printed but not linked: 343

  1. Gibbons, 2013, The next steps in developing clinical practice guidelines for prevention, Circulation, 128, 1716, 10.1161/CIRCULATIONAHA.113.005548 · DOI
  2. Gibbons, 2013, Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute, Circulation, 128, 1713, 10.1161/CIRCULATIONAHA.113.004587 · DOI
  3. Anderson, 2014, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, Circulation, 129, 2329, 10.1161/CIR.0000000000000042 · DOI · Paper page
  4. Halperin, 2016, Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 133, 1426, 10.1161/CIR.0000000000000312 · DOI · Paper page
  5. Jacobs, 2013, ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 127, 268, 10.1161/CIR.0b013e31827e8e5f · DOI
  6. Jacobs, 2014, The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 130, 1208, 10.1161/CIR.0000000000000090 · DOI · Paper page
  7. Arnett, 2014, Circulation, 130, 1662, 10.1161/CIR.0000000000000128 · DOI · Paper page
  8. Whelton, 2018, Circulation, 71, e13
  9. Gibbons, 2013, The next steps in developing clinical practice guidelines for prevention, Circulation, 128, 1716, 10.1161/CIRCULATIONAHA.113.005548 · DOI
  10. Gibbons, 2013, Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute, Circulation, 128, 1713, 10.1161/CIRCULATIONAHA.113.004587 · DOI
  11. 1967, Effects of treatment on morbidity and mortality in hypertension. I. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg, JAMA, 202, 1028, 10.1001/jama.1967.03130240070013 · DOI · Paper page
  12. 1970, Effects of treatment on morbidity and mortality in hypertension: II. results in patients with diastolic blood pressure averaging 90 through 114 mm Hg, JAMA, 213, 1143, 10.1001/jama.1970.03170330025003 · DOI · Paper page
  13. 1977, Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study, JAMA, 237, 255, 10.1001/jama.1977.03270300059008 · DOI · Paper page
  14. Moser, 2013, The treatment of hypertension: a remarkable success story, J Clin Hypertens (Greenwich), 15, 88, 10.1111/jch.12033 · DOI
  15. Reboussin, 2018, Hypertension, 71, e116, 10.1161/HYP.0000000000000067 · DOI · Paper page
  16. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128, e240, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  17. Gerhard-Herman, 2017, 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 135, e726, 10.1161/CIR.0000000000000471 · DOI · Paper page
  18. Lenders, 2014, Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 99, 1915, 10.1210/jc.2014-1498 · DOI · Paper page
  19. January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, Circulation, 130, e199, 10.1161/CIR.0000000000000041 · DOI · Paper page
  20. Nishimura, 2017, 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 135, e1159, 10.1161/CIR.0000000000000503 · DOI · Paper page
  21. Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129(suppl 2), S49, 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
  22. 2013, Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
  23. Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 · DOI · Paper page
  24. O'Gara, 2013, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 127, e362, 10.1161/CIR.0b013e3182742c84 · DOI · Paper page
  25. Regitz-Zagrosek, 2011, ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC), Eur Heart J, 32, 3147, 10.1093/eurheartj/ehr218 · DOI · Paper page
  26. Greenland, 2010, 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 122, e584, 10.1161/CIR.0b013e3182051b4c · DOI · Paper page
  27. Hiratzka, 2010, Circulation, 121, e266, 10.1161/CIR.0b013e3181d4739e · DOI · Paper page
  28. 2004, The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents, Pediatrics, 114, 555, 10.1542/peds.114.2.S2.555 · DOI · Paper page
  29. Brush, 2015, 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers, J Am Coll Cardiol, 65, 2118, 10.1016/j.jacc.2015.03.550 · DOI
  30. Rosendorff, 2015, Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension, Circulation, 131, e435, 10.1161/CIR.0000000000000207 · DOI · Paper page
  31. Flynn, 2014, Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association, Hypertension, 63, 1116, 10.1161/HYP.0000000000000007 · DOI · Paper page
  32. Go, 2014, An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention, Hypertension, 63, 878, 10.1161/HYP.0000000000000003 · DOI · Paper page
  33. O'Brien, 2013, European Society of Hypertension position paper on ambulatory blood pressure monitoring, J Hypertens, 31, 1731, 10.1097/HJH.0b013e328363e964 · DOI · Paper page
  34. Drozda, 2011, Circulation, 124, 248, 10.1161/CIR.0b013e31821d9ef2 · DOI · Paper page
  35. Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141 · DOI · Paper page
  36. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  37. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  38. Rapsomaniki, 2014, Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people, Lancet, 383, 1899, 10.1016/S0140-6736(14)60685-1 · DOI · Paper page
  39. Rutan, 1988, Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial, Circulation, 77, 504, 10.1161/01.CIR.77.3.504 · DOI · Paper page
  40. Sesso, 2000, Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men, Hypertension, 36, 801, 10.1161/01.HYP.36.5.801 · DOI · Paper page
  41. Benetos, 2002, Prognostic value of systolic and diastolic blood pressure in treated hypertensive men, Arch Intern Med, 162, 577, 10.1001/archinte.162.5.577 · DOI · Paper page
  42. Lindenstrom, 1995, Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study, Am J Epidemiol, 142, 1279, 10.1093/oxfordjournals.aje.a117595 · DOI
  43. Zhao, 2014, Brachial pulse pressure and cardiovascular or all-cause mortality in the general population: a meta-analysis of prospective observational studies, J Clin Hypertens (Greenwich), 16, 678, 10.1111/jch.12375 · DOI
  44. Mosley, 2007, Predictive utility of pulse pressure and other blood pressure measures for cardiovascular outcomes, Hypertension, 49, 1256, 10.1161/HYPERTENSIONAHA.106.083592 · DOI
  45. Franklin, 2009, Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study, Circulation, 119, 243, 10.1161/CIRCULATIONAHA.108.797936 · DOI · Paper page
  46. Kodama, 2014, Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus, Am J Cardiol, 113, 1058, 10.1016/j.amjcard.2013.12.005 · DOI
  47. Lim, 2012, A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2224, 10.1016/S0140-6736(12)61766-8 · DOI · Paper page
  48. Ford, 2011, Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States, Circulation, 123, 1737, 10.1161/CIRCULATIONAHA.110.005645 · DOI · Paper page
  49. Cheng, 2014, Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study, Circulation, 130, 820, 10.1161/CIRCULATIONAHA.113.008506 · DOI · Paper page
  50. Willey, 2014, Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study, J Am Heart Assoc, 3
  51. Saran, 2015, US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States, Am J Kidney Dis, 66 Svii, S1
  52. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  53. Rapsomaniki, 2014, Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people, Lancet, 383, 1899, 10.1016/S0140-6736(14)60685-1 · DOI · Paper page
  54. Guo, 2013, Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies, Curr Hypertens Rep, 15, 703, 10.1007/s11906-013-0403-y · DOI
  55. Guo, 2013, Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies, PLoS ONE, 8
  56. Huang, 2014, Prehypertension and the risk of stroke: a meta-analysis, Neurology, 82, 1153, 10.1212/WNL.0000000000000268 · DOI
  57. Huang, 2015, Prehypertension and the risk of coronary heart disease in Asian and Western populations: a meta-analysis, J Am Heart Assoc, 4
  58. Huang, 2014, Prehypertension and Incidence of ESRD: a systematic review and meta-analysis, Am J Kidney Dis, 63, 76, 10.1053/j.ajkd.2013.07.024 · DOI
  59. Huang, 2014, Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis, Am Heart J, 167, 160, 10.1016/j.ahj.2013.10.023 · DOI · Paper page
  60. Huang, 2013, Prehypertension and incidence of cardiovascular disease: a meta-analysis, BMC Med, 11, 177, 10.1186/1741-7015-11-177 · DOI · Paper page
  61. Lee, 2011, Presence of baseline prehypertension and risk of incident stroke: a meta-analysis, Neurology, 77, 1330, 10.1212/WNL.0b013e3182315234 · DOI
  62. Shen, 2013, Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease, Am J Cardiol, 112, 266, 10.1016/j.amjcard.2013.03.023 · DOI
  63. Sundstrom, 2015, Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis, Ann Intern Med, 162, 184, 10.7326/M14-0773 · DOI · Paper page
  64. Wang, 2013, Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population: a meta-analysis of prospective cohort studies, Int J Cardiol, 168, 4857, 10.1016/j.ijcard.2013.07.063 · DOI
  65. Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 · DOI · Paper page
  66. Muntner, 2010, Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis, Hypertension, 55, 1339, 10.1161/HYPERTENSIONAHA.109.149609 · DOI
  67. Parikh, 2008, A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study, Ann Intern Med, 148, 102, 10.7326/0003-4819-148-2-200801150-00005 · DOI · Paper page
  68. Carson, 2011, Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis, Hypertension, 57, 1101, 10.1161/HYPERTENSIONAHA.110.168005 · DOI · Paper page
  69. Vasan, 2002, Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study, JAMA, 287, 1003, 10.1001/jama.287.8.1003 · DOI · Paper page
  70. Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 · DOI · Paper page
  71. Weir, 2014, In the clinic: hypertension, Ann Intern Med, 161, ITC1, 10.7326/0003-4819-161-11-201412020-01006 · DOI
  72. Liu, 2016, Comparison of stethoscope bell and diaphragm, and of stethoscope tube length, for clinical blood pressure measurement, Blood Press Monit, 21, 178, 10.1097/MBP.0000000000000175 · DOI
  73. Kantola, 2005, Bell or diaphragm in the measurement of blood pressure?, J Hypertens, 23, 499, 10.1097/01.hjh.0000160204.74028.95 · DOI
  74. Siu, 2015, Screening for high blood pressure in adults: US Preventive Services Task Force recommendation statement, Ann Intern Med, 163, 778, 10.7326/M15-2223 · DOI · Paper page
  75. Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 · DOI · Paper page
  76. Pickering, 2008, Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association, Hypertension, 52, 10, 10.1161/HYPERTENSIONAHA.107.189010 · DOI · Paper page
  77. Pickering, 1988, How common is white coat hypertension?, JAMA, 259, 225, 10.1001/jama.1988.03720020027031 · DOI · Paper page
  78. Piper, 2015, Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the US Preventive Services Task Force, Ann Intern Med, 162, 192, 10.7326/M14-1539 · DOI · Paper page
  79. Ohkubo, 2005, Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study, J Am Coll Cardiol, 46, 508, 10.1016/j.jacc.2005.03.070 · DOI · Paper page
  80. Fagard, 2007, Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis, J Hypertens, 25, 2193, 10.1097/HJH.0b013e3282ef6185 · DOI · Paper page
  81. Asayama, 2014, Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population, Hypertension, 64, 935, 10.1161/HYPERTENSIONAHA.114.03614 · DOI · Paper page
  82. Mancia, 2013, Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements, Hypertension, 62, 168, 10.1161/HYPERTENSIONAHA.111.00690 · DOI
  83. Pierdomenico, 2011, Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis, Am. J Hypertens, 24, 52, 10.1038/ajh.2010.203 · DOI · Paper page
  84. Viera, 2010, Reproducibility of masked hypertension in adults with untreated borderline office blood pressure: comparison of ambulatory and home monitoring, Am. J Hypertens, 23, 1190, 10.1038/ajh.2010.158 · DOI
  85. Viera, 2014, Reproducibility of masked hypertension among adults 30 years or older, Blood Press Monit, 19, 208, 10.1097/MBP.0000000000000054 · DOI
  86. Stergiou, 2014, Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome, Hypertension, 63, 675, 10.1161/HYPERTENSIONAHA.113.02741 · DOI · Paper page
  87. Tomiyama, 2006, Masked hypertension and target organ damage in treated hypertensive patients, Am J Hypertens, 19, 880, 10.1016/j.amjhyper.2006.03.006 · DOI
  88. Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141 · DOI · Paper page
  89. Funder, 2016, The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, 101, 1889, 10.1210/jc.2015-4061 · DOI · Paper page
  90. Pedrosa, 2011, Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension, Hypertension, 58, 811, 10.1161/HYPERTENSIONAHA.111.179788 · DOI · Paper page
  91. Kump, 1994, Assessment of the validity and utility of a sleep-symptom questionnaire, Am J Respir Crit Care Med, 150, 735, 10.1164/ajrccm.150.3.8087345 · DOI · Paper page
  92. Lenders, 2014, Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 99, 1915, 10.1210/jc.2014-1498 · DOI · Paper page
  93. Lurbe, 2009, Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension, J Hypertens, 27, 1719, 10.1097/HJH.0b013e32832f4f6b · DOI · Paper page
  94. Berglund, 1976, Prevalence of primary and secondary hypertension: studies in a random population sample, Br Med J, 2, 554, 10.1136/bmj.2.6035.554 · DOI · Paper page
  95. Hassan-Smith, 2011, Inherited forms of mineralocorticoid hypertension, Curr Opin Endocrinol Diabetes Obes, 18, 177, 10.1097/MED.0b013e3283469444 · DOI
  96. Katznelson, 2014, Acromegaly: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 99, 3933, 10.1210/jc.2014-2700 · DOI · Paper page
  97. Cortese, 2013, Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol, Psychiatry, 54, 227
  98. Wolraich, 2011, ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents, Pediatrics, 128, 1007, 10.1542/peds.2011-2654 · DOI · Paper page
  99. Newcomer, 2007, Metabolic considerations in the use of antipsychotic medications: a review of recent evidence, J Clin Psychiatry, 68, 20
  100. Willey, 2014, Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study, J Am Heart Assoc, 3
  101. Liu, 2013, Immunosuppressant utilization and cardiovascular complications among Chinese patients after kidney transplantation: a systematic review and analysis, Int Urol Nephrol, 45, 885, 10.1007/s11255-012-0294-x · DOI
  102. Penninga, 2013, Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients, Cochrane Database Syst Rev, 5, CD008817
  103. Xue, 2014, Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis, Chin Med J, 127, 2376, 10.3760/cma.j.issn.0366-6999.20140518 · DOI
  104. Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 · DOI · Paper page
  105. Montori, 2002, Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature, Endocrinol Metab Clin North Am, 31, 619, 10.1016/S0889-8529(02)00013-0 · DOI · Paper page
  106. Cooper, 2014, Stenting and medical therapy for atherosclerotic renal-artery stenosis, N Engl J Med, 370, 13, 10.1056/NEJMoa1310753 · DOI · Paper page
  107. Riaz, 2014, Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis, Am J Cardiol, 114, 1116, 10.1016/j.amjcard.2014.06.033 · DOI
  108. Barbe, 2010, Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea, Am J Respir Crit Care Med, 181, 718, 10.1164/rccm.200901-0050OC · DOI · Paper page
  109. Martinez-Garcia, 2013, Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial, JAMA, 310, 2407, 10.1001/jama.2013.281250 · DOI · Paper page
  110. Lozano, 2010, Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial, J Hypertens, 28, 2161, 10.1097/HJH.0b013e32833b9c63 · DOI · Paper page
  111. Pedrosa, 2013, Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial, Chest, 144, 1487, 10.1378/chest.13-0085 · DOI · Paper page
  112. Whelton, 1997, Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group, Am J Clin Nutr, 65, 652S, 10.1093/ajcn/65.2.652S · DOI
  113. 1992, The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I, JAMA, 267, 1213, 10.1001/jama.1992.03480090061028 · DOI · Paper page
  114. Appel, 2003, Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial, JAMA, 289, 2083
  115. Appel, 1997, A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group, N Engl J Med, 336, 1117, 10.1056/NEJM199704173361601 · DOI · Paper page
  116. Graudal, 2012, Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review), Am J Hypertens, 25, 1, 10.1038/ajh.2011.210 · DOI · Paper page
  117. Whelton, 1997, Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials, JAMA, 277, 1624, 10.1001/jama.1997.03540440058033 · DOI · Paper page
  118. Geleijnse, 2003, Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials, J Hum Hypertens, 17, 471, 10.1038/sj.jhh.1001575 · DOI · Paper page
  119. Whelton, 2014, Health effects of sodium and potassium in humans, Curr Opin Lipidol, 25, 75, 10.1097/MOL.0000000000000033 · DOI
  120. Aburto, 2013, Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses, BMJ, 346
  121. Carlson, 2014, Isometric exercise training for blood pressure management: a systematic review and meta-analysis, Mayo Clin Proc, 89, 327, 10.1016/j.mayocp.2013.10.030 · DOI · Paper page
  122. Garcia-Hermoso, 2013, Effects of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials, Obes Rev, 14, 919, 10.1111/obr.12054 · DOI
  123. Rossi, 2013, The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example, Can J Cardiol, 29, 622, 10.1016/j.cjca.2013.02.010 · DOI
  124. Stewart, 2008, Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study, Addiction, 103, 1622, 10.1111/j.1360-0443.2008.02317.x · DOI
  125. Lang, 1995, Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group, J Epidemiol Community Health, 49, 610, 10.1136/jech.49.6.610 · DOI
  126. Lloyd-Jones, 2005, Hypertension in adults across the age spectrum: current outcomes and control in the community, JAMA, 294, 466, 10.1001/jama.294.4.466 · DOI · Paper page
  127. Ozyilmaz, 2013, Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events, Nephrol Dial Transplant, 28, 2805, 10.1093/ndt/gft254 · DOI
  128. Peters, 2013, Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals, Stroke, 44, 2394, 10.1161/STROKEAHA.113.001624 · DOI
  129. Lawes, 2002, Blood pressure and coronary heart disease: a review of the evidence, Semin Vasc Med, 2, 355, 10.1055/s-2002-36765 · DOI
  130. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  131. Takashima, 2012, Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years, J Hypertens, 30, 2299, 10.1097/HJH.0b013e328359a9f7 · DOI
  132. Murakami, 2014, Meta-analyses using individual participant data from cardiovascular cohort studies in Japan: current status and future directions, J Epidemiol, 24, 96
  133. van Dieren, 2012, Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes, Diabetes Res Clin Pract, 98, 83, 10.1016/j.diabres.2012.05.002 · DOI
  134. Sundstrom, 2014, Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data, Lancet, 384, 591, 10.1016/S0140-6736(14)61212-5 · DOI · Paper page
  135. Turnbull, 2005, Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials, Arch Intern Med, 165, 1410, 10.1001/archinte.165.12.1410 · DOI · Paper page
  136. Wang, 2005, Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome, Hypertension, 45, 907, 10.1161/01.HYP.0000165020.14745.79 · DOI · Paper page
  137. Turnbull, 2008, Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials, Eur Heart J, 29, 2669, 10.1093/eurheartj/ehn427 · DOI · Paper page
  138. Turnbull, 2008, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials, BMJ, 336, 1121, 10.1136/bmj.39548.738368.BE · DOI · Paper page
  139. Czernichow, 2010, Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial, Hypertension, 55, 1193, 10.1161/HYPERTENSIONAHA.109.140624 · DOI
  140. Heerspink, 2010, Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease, Eur Heart J, 31, 2888, 10.1093/eurheartj/ehq139 · DOI
  141. Ninomiya, 2010, Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial, J Hypertens, 28, 1141, 10.1097/HJH.0b013e328338a89c · DOI
  142. Collier, 2011, Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), J Hypertens, 29, 583, 10.1097/HJH.0b013e328342c845 · DOI
  143. Ninomiya, 2013, Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials, BMJ, 347
  144. Redon, 2012, Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial), J Am Coll Cardiol, 59, 74, 10.1016/j.jacc.2011.09.040 · DOI · Paper page
  145. Ogden, 2000, Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification, Hypertension, 35, 539, 10.1161/01.HYP.35.2.539 · DOI · Paper page
  146. van der Leeuw, 2015, Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation, Hypertension, 65, 115, 10.1161/HYPERTENSIONAHA.114.04421 · DOI
  147. Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, 10.1136/bmj.b1665 · DOI · Paper page
  148. Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8 · DOI · Paper page
  149. Sundstrom, 2014, Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data, Lancet, 384, 591, 10.1016/S0140-6736(14)61212-5 · DOI · Paper page
  150. Thomopoulos, 2014, Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials, J Hypertens, 32, 2296, 10.1097/HJH.0000000000000379 · DOI · Paper page
  151. Sundstrom, 2015, Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis, Ann Intern Med, 162, 184, 10.7326/M14-0773 · DOI · Paper page
  152. Thompson, 2011, Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis, JAMA, 305, 913, 10.1001/jama.2011.250 · DOI · Paper page
  153. Xie, 2015, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3 · DOI · Paper page
  154. Czernichow, 2011, The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials, J Hypertens, 29, 4, 10.1097/HJH.0b013e32834000be · DOI · Paper page
  155. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  156. van Dieren, 2012, Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes, Diabetes Res Clin Pract, 98, 83, 10.1016/j.diabres.2012.05.002 · DOI
  157. Montgomery, 2003, The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis, J Hypertens, 21, 1753, 10.1097/00004872-200309000-00026 · DOI
  158. Kassai, 2005, Treatment of high blood pressure and gain in event-free life expectancy, Vasc Health Risk Manag, 1, 163, 10.2147/vhrm.1.2.163.64086 · DOI
  159. Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129(suppl 2), S49, 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
  160. Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129(suppl 2), S1, 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  161. Ambrosius, 2014, The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT), Clin Trials, 11, 532, 10.1177/1740774514537404 · DOI · Paper page
  162. Cushman, 2007, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 44i, 10.1016/j.amjcard.2007.03.005 · DOI · Paper page
  163. Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2 · DOI · Paper page
  164. Xie, 2015, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3 · DOI · Paper page
  165. Verdecchia, 2016, More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis, Hypertension, 68, 642, 10.1161/HYPERTENSIONAHA.116.07608 · DOI
  166. Bangalore, 2017, Optimal systolic blood pressure target after SPRINT insights from a network meta-analysis of randomized trials, Am J Med, 30, 707, 10.1016/j.amjmed.2017.01.004 · DOI · Paper page
  167. Julius, 2006, Feasibility of treating prehypertension with an angiotensin-receptor blocker, N Engl J Med, 354, 1685, 10.1056/NEJMoa060838 · DOI · Paper page
  168. Lawes, 2002, Blood pressure and coronary heart disease: a review of the evidence, Semin Vasc Med, 2, 355, 10.1055/s-2002-36765 · DOI
  169. Lonn, 2016, Blood-pressure lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med, 374, 2009, 10.1056/NEJMoa1600175 · DOI · Paper page
  170. Neaton, 1993, Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group, JAMA, 270, 713, 10.1001/jama.1993.03510060059034 · DOI · Paper page
  171. Reboussin, 2018, Circulation, 71, e116
  172. Psaty, 2003, Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis, JAMA, 289, 2534, 10.1001/jama.289.19.2534 · DOI · Paper page
  173. Ambrosius, 2014, The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT), Clin Trials, 11, 532, 10.1177/1740774514537404 · DOI · Paper page
  174. Cushman, 2007, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 44i, 10.1016/j.amjcard.2007.03.005 · DOI · Paper page
  175. Ambrosius, 2014, The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT), Clin Trials, 11, 532, 10.1177/1740774514537404 · DOI · Paper page
  176. Cushman, 2007, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 44i, 10.1016/j.amjcard.2007.03.005 · DOI · Paper page
  177. Xu, 2015, Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study, BMJ, 350, h158, 10.1136/bmj.h158 · DOI · Paper page
  178. Brennan, 2010, Disease management to promote blood pressure control among African Americans, Popul Health Manag, 13, 65, 10.1089/pop.2009.0019 · DOI
  179. Bosworth, 2009, Two self-management interventions to improve hypertension control: a randomized trial, Ann Intern Med, 151, 687, 10.7326/0000605-200911170-00148 · DOI · Paper page
  180. Bosworth, 2011, Home blood pressure management and improved blood pressure control: results from a randomized controlled trial, Arch Intern Med, 171, 1173, 10.1001/archinternmed.2011.276 · DOI · Paper page
  181. Green, 2008, Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial, JAMA, 299, 2857, 10.1001/jama.299.24.2857 · DOI · Paper page
  182. Heisler, 2012, Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial, Circulation, 125, 2863, 10.1161/CIRCULATIONAHA.111.089169 · DOI
  183. Margolis, 2013, Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial, JAMA, 310, 46, 10.1001/jama.2013.6549 · DOI · Paper page
  184. Aronow, 2011, Circulation, 123, 2434, 10.1161/CIR.0b013e31821daaf6 · DOI · Paper page
  185. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128, e240, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  186. Fihn, 2014, Circulation, 130, 1749, 10.1161/CIR.0000000000000095 · DOI · Paper page
  187. Gerhard-Herman, 2017, 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 135, e726, 10.1161/CIR.0000000000000471 · DOI · Paper page
  188. Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939 · DOI · Paper page
  189. Bundy, 2017, Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis, JAMA Cardiol, 2, 775, 10.1001/jamacardio.2017.1421 · DOI · Paper page
  190. Zanchetti, 2006, Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial, J Hypertens, 24, 2163, 10.1097/01.hjh.0000249692.96488.46 · DOI · Paper page
  191. 2003, Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Hypertension, 42, 239, 10.1161/01.HYP.0000086521.95630.5A · DOI · Paper page
  192. Fihn, 2014, Circulation, 130, 1749, 10.1161/CIR.0000000000000095 · DOI · Paper page
  193. Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, 10.1136/bmj.b1665 · DOI · Paper page
  194. Leon, 1981, Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris, Am J Cardiol, 48, 131, 10.1016/0002-9149(81)90582-8 · DOI · Paper page
  195. de Peuter, 2009, A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure, Neth J Med, 67, 284
  196. Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468 · DOI · Paper page
  197. Thomopoulos, 2016, Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials, J Hypertens, 34, 613, 10.1097/HJH.0000000000000881 · DOI · Paper page
  198. Xie, 2015, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3 · DOI · Paper page
  199. Pfeffer, 2015, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial, Circulation, 131, 34, 10.1161/CIRCULATIONAHA.114.013255 · DOI · Paper page
  200. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128, e240, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page

200 of 343 shown

Cited by

See all 947

Metadata

Authors
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T.
Venue
Journal of the American Society of Hypertension
Publisher
Elsevier BV
Published
2018-08
Volume
12
Issue
8
Pages
579.e1-579.e73
ISSN
  • 1878-7436 (ISSN-L)
  • 1933-1711
DOI
10.1016/j.jash.2018.06.010
OpenAlex
W3138221603
Cited by
947
References
90
FWCI
152.25
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. https://app.cochat.ai/papers/10.1016/j.jash.2018.06.010
The paper
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., . . . Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. Journal of the American Society of Hypertension. https://doi.org/10.1016/j.jash.2018.06.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.